CINN‑103
Solid Tumor Immunotherapy
PreclinicalActive
Key Facts
About Cinnagen
Cinnagen leverages a self‑amplifying mRNA platform to create durable, low‑dose therapeutics for rare diseases and cancer.
View full company profileSolid Tumor Immunotherapy
Cinnagen leverages a self‑amplifying mRNA platform to create durable, low‑dose therapeutics for rare diseases and cancer.
View full company profile